PLoS Genetics (Nov 2017)

Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease.

  • Maria Victoria Fernández,
  • Jong Hun Kim,
  • John P Budde,
  • Kathleen Black,
  • Alexandra Medvedeva,
  • Ben Saef,
  • Yuetiva Deming,
  • Jorge Del-Aguila,
  • Laura Ibañez,
  • Umber Dube,
  • Oscar Harari,
  • Joanne Norton,
  • Rachel Chasse,
  • John C Morris,
  • Alison Goate,
  • NIA-LOAD family study group,
  • NCRAD,
  • Carlos Cruchaga

DOI
https://doi.org/10.1371/journal.pgen.1007045
Journal volume & issue
Vol. 13, no. 11
p. e1007045

Abstract

Read online

Alzheimer disease (AD), Frontotemporal lobar degeneration (FTD), Amyotrophic lateral sclerosis (ALS) and Parkinson disease (PD) have a certain degree of clinical, pathological and molecular overlap. Previous studies indicate that causative mutations in AD and FTD/ALS genes can be found in clinical familial AD. We examined the presence of causative and low frequency coding variants in the AD, FTD, ALS and PD Mendelian genes, in over 450 families with clinical history of AD and over 11,710 sporadic cases and cognitive normal participants from North America. Known pathogenic mutations were found in 1.05% of the sporadic cases, in 0.69% of the cognitively normal participants and in 4.22% of the families. A trend towards enrichment, albeit non-significant, was observed for most AD, FTD and PD genes. Only PSEN1 and PINK1 showed consistent association with AD cases when we used ExAC as the control population. These results suggest that current study designs may contain heterogeneity and contamination of the control population, and that current statistical methods for the discovery of novel genes with real pathogenic variants in complex late onset diseases may be inadequate or underpowered to identify genes carrying pathogenic mutations.